

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**LANSSEN PHARMACEUTICAL HOLDINGS LIMITED**

**朗生醫藥控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 503)**

**INSIDE INFORMATION  
IN RELATION TO SECOND SHARE REDUCTION PLAN OF STARRY**

Lanssen Pharmaceutical Holdings Limited (the “Company”) makes this announcement pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the announcement of the Company dated 9 March 2017 in relation to share reduction plan (the “First Share Reduction Plan”) of Zhejiang Starry Pharmaceutical Co., Ltd. (“Starry”). Pursuant to the First Share Reduction Plan, Lanssen Investments (Hong Kong) Limited (“Lanssen HK”) and Full Keen Limited (“Full Keen”), both indirect wholly owned subsidiaries of the Company, would dispose of not more than an aggregate of 9,675,000 shares of Starry (the “Starry Shares”) during a period of six months commencing on the third trading day of the Shanghai Stock Exchange immediately following 10 March 2017 (or a period of six month commencing on the 15th trading day of the Shanghai Stock Exchange immediately following 10 March 2017 for reduction of Starry Shares through centralised competitive bidding system on the Shanghai Stock Exchange).

As at the date of this announcement, Lanssen HK and Full Keen disposed an aggregate of 4,175,000 Starry Shares. Please refer to the announcement and the circular of the Company dated 15 March 2017 and 28 April 2017 respectively for details of such disposal.

The Company announces that on 19 September 2017 Lanssen HK notified Starry about the second share reduction plan (the “Second Share Reduction Plan”) in relation to its holding in the Starry Shares and the key points are:

- Number of Starry Shares to be disposed: not more than 5,500,000 Starry Shares, representing not more than 4.583% of the total number of issued shares in Starry.

- Share reduction period: commencing on the third trading day of the Shanghai Stock Exchange immediately following 20 September 2017, the date of Starry's announcement of the Second Share Reduction Plan (or commencing on the 15th trading day of the Shanghai Stock Exchange immediately following 20 September 2017 for reduction of Starry Shares through centralised competitive bidding on the Shanghai Stock Exchange) to 8 March 2018.
- Methods of share reduction: through (a) block trade sales; or (b) centralised competitive bidding system on the Shanghai Stock Exchange, provided that total amount of share reduction through block trade sales and the centralised competitive bidding system in any consecutive three months period shall not exceed 2% and 1% of the total number of issued shares in Starry respectively.
- Share reduction price: with reference to the prevailing trading price of Starry Shares on the Shanghai Stock Exchange.

The notification of the Second Share Reduction Plan was given by Lansen HK to Starry in accordance with the relevant rules and regulations of the China Securities Regulatory Commission, governing share reduction by a substantial shareholder holding more than 5% interest in a listed issuer.

As at the date of this announcement, no definitive or legally binding agreement relating to disposal of Starry Shares has been entered into by the Company or Lansen HK. If any disposal under the Second Share Reduction Plan materialises, it may constitute a notifiable transaction under Chapter 14 of the Listing Rules. The Company will comply with the applicable requirements under the Listing Rules accordingly and make further announcement(s) in this regard as and when appropriate.

**As the disposal under the Second Share Reduction Plan may or may not proceed, shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Lansen Pharmaceutical Holdings Limited**  
**Wu Zhen Tao**  
*Chairman*

Hong Kong, 19 September 2017

*As at the date of this announcement, the executive Directors are Mr. Liu Bang Min and Mr. Hou Song; the non-executive Directors are Mr. Wu Zhen Tao, Mr. Lee Jin Yi, Mr. Stephen Burnau Hunt and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Tang Chiu Ping, Raymond and Mr. Fritz Heinrich Horlacher.*